Novel therapy in the treatment of scleroderma

Research output: Contribution to journalReview articlepeer-review


While the biology of the pathogenesis of scleroderma is continually being better understood, there still is no single agent or therapeutic combination that has a clear impact on the disease process. Traditional medications (colchicine, potassium aminobenzoate (potaba), D-penicillamine) are disappointing in clinical practice despite anecdotal evidence of benefit. Furthermore, the most popular traditional drug, D-penicillamine, failed to clearly show benefit when tested in a well-designed clinical trial comparing conventional high dose with a very low dose (125 mg po. q.i.d.) [1]. Currently, most success in managing scleroderma and improving quality of life is secondary to organ-specific therapy, such as management of a renal crisis with an ACE inhibitor, treatment of Raynaud's phenomenon with calcium channel blockers, or control of serious gastrointestinal reflux disease with a proton pump inhibitor. In this review we will focus on novel therapies that are currently being tested in the treatment of scleroderma and have the potential of modifying the disease process and overall clinical outcome. We have attempted to review the rationale for each agent, recognising that its true biological effect will only be determined in clinical trials.

Original languageEnglish (US)
Pages (from-to)31-48
Number of pages18
JournalExpert Opinion on Investigational Drugs
Issue number1
StatePublished - Jan 11 2001


  • Angiotensin II inhibitors
  • Cytokines
  • D-penicillamine
  • Halofuginone
  • Inflammation
  • Minocycline
  • Pentoxifylline
  • Scleroderma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Novel therapy in the treatment of scleroderma'. Together they form a unique fingerprint.

Cite this